OrbusNeich to trial Genous follow-up
This article was originally published in Clinica
Executive Summary
OrbusNeich has kicked off a randomised clinical trial of its Combo stent. The sirolimus-eluting device will be up against Boston Scientific's paclitaxel-eluting Taxus Liberté stent in the 180-patient study.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.